- Email: [email protected]
Erratum to “Prognosis of patients with chronic hepatitis B in France (2008–2013): A nationwide, observational and hospital-based study”
Erratum
Erratum to ‘‘Prognosis of patients with chronic hepatitis B in France (2008–2013): A nationwide, observational and hospital-based study” Vincent Mallet1,2,3,⇑, Kamal Hamed4, Michaël Schwarzinger5,6 1
Université Paris Descartes, Sorbonne Paris Cité, Paris, France; 2Institut Pasteur, Institut National de la Santé et de la Recherche Médicale (Inserm), Unité 1223, Paris, France; 3Hepatology Service, Assistance Publique—Hôpitaux de Paris (AP—HP), Groupe Hospitalier Cochin Port-Royal, Paris, France; 4Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA; 5Translational Health Economics Network (THEN), Paris, France; 6Infection Antimicrobials Modeling & Evolution (IAME), UMR 1137, Institut National de la Santé et de la Recherche Médicale (INSERM) – Université Paris Diderot, Sorbonne Paris Cité, France
It has come to our attention that an error was introduced in Fig. 2 of this manuscript at the editorial stage of publication. The error consisted of the incorrect placement of the y axis, which should have intersected the x axis at 1. The corrected version of the figure may be found below. The editorial office would like to apologise for any inconvenience caused.
Liver-related risk factors Co-infection with HDV Co-infection with HCV Alcohol use disorders Diabetes Other causes of cirrhosis Non-liver-related risk factors Co-infection with HIV AIDS in 2008-2013 Former AIDS (before 2008) No AIDS recorded otherwise CKD at cohort inception Kidney transplant recipient On dialysis CKD otherwise Cancer other than HCC Cardiovascular disease Respiratory disease
Hepatocellular carcinoma End-stage liver disease Liver disease progression
0
1
2
3
4
5
Multivariate-adjusted hazard ratio (95% confidence interval) Fig. 2. Risk factors of liver disease progression of CHB patients in the 2008–2013 French hospital database (N = 48,189). Follow-up was from January 2008 to liver disease progression, a composite outcome of end-stage liver disease and/or hepatocellular carcinoma, or to last discharge. Patients with chronic kidney disease were censored at kidney transplantation (n = 253) in 2008–2013. All risk factors under study were recorded before liver disease progression. aHR, adjusted hazard ratio; CI, confidence interval; CKD, chronic kidney disease; HCC, hepatocellular carcinoma; HDV, hepatitis D virus; HCV, hepatitis C virus; HIV, human immunodeficiency virus.
q
DOI of original article: http://dx.doi.org/10.1016/j.jhep.2016.10.031. Corresponding author. Address: Hôpitaux de Paris, Groupe Hospitalier Cochin Port-Royal, Hepatology service, 27 rue du faubourg Saint Jacques, 75014 Paris, France. Tel.: +33 6 14 08 20 96. E-mail address: [email protected] (V. Mallet). ⇑
Journal of Hepatology 2017 vol. xxx j xxx–xxx
Please cite this article in press as: Mallet V et al. Erratum to ‘‘Prognosis of patients with chronic hepatitis B in France (2008–2013): A nationwide, observational and hospital-based study”. J Hepatol (2017), http://dx.doi.org/10.1016/j.jhep.2017.02.016
Erratum to ‘‘Prognosis of patients with chronic hepatitis B in France (2008–2013): A nationwide, observational and hospital-based study” Vincent Mallet1,2,3,⇑, Kamal Hamed4, Michaël Schwarzinger5,6 1
Université Paris Descartes, Sorbonne Paris Cité, Paris, France; 2Institut Pasteur, Institut National de la Santé et de la Recherche Médicale (Inserm), Unité 1223, Paris, France; 3Hepatology Service, Assistance Publique—Hôpitaux de Paris (AP—HP), Groupe Hospitalier Cochin Port-Royal, Paris, France; 4Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA; 5Translational Health Economics Network (THEN), Paris, France; 6Infection Antimicrobials Modeling & Evolution (IAME), UMR 1137, Institut National de la Santé et de la Recherche Médicale (INSERM) – Université Paris Diderot, Sorbonne Paris Cité, France
It has come to our attention that an error was introduced in Fig. 2 of this manuscript at the editorial stage of publication. The error consisted of the incorrect placement of the y axis, which should have intersected the x axis at 1. The corrected version of the figure may be found below. The editorial office would like to apologise for any inconvenience caused.
Liver-related risk factors Co-infection with HDV Co-infection with HCV Alcohol use disorders Diabetes Other causes of cirrhosis Non-liver-related risk factors Co-infection with HIV AIDS in 2008-2013 Former AIDS (before 2008) No AIDS recorded otherwise CKD at cohort inception Kidney transplant recipient On dialysis CKD otherwise Cancer other than HCC Cardiovascular disease Respiratory disease
Hepatocellular carcinoma End-stage liver disease Liver disease progression
0
1
2
3
4
5
Multivariate-adjusted hazard ratio (95% confidence interval) Fig. 2. Risk factors of liver disease progression of CHB patients in the 2008–2013 French hospital database (N = 48,189). Follow-up was from January 2008 to liver disease progression, a composite outcome of end-stage liver disease and/or hepatocellular carcinoma, or to last discharge. Patients with chronic kidney disease were censored at kidney transplantation (n = 253) in 2008–2013. All risk factors under study were recorded before liver disease progression. aHR, adjusted hazard ratio; CI, confidence interval; CKD, chronic kidney disease; HCC, hepatocellular carcinoma; HDV, hepatitis D virus; HCV, hepatitis C virus; HIV, human immunodeficiency virus.
q
DOI of original article: http://dx.doi.org/10.1016/j.jhep.2016.10.031. Corresponding author. Address: Hôpitaux de Paris, Groupe Hospitalier Cochin Port-Royal, Hepatology service, 27 rue du faubourg Saint Jacques, 75014 Paris, France. Tel.: +33 6 14 08 20 96. E-mail address: [email protected] (V. Mallet). ⇑
Journal of Hepatology 2017 vol. xxx j xxx–xxx
Please cite this article in press as: Mallet V et al. Erratum to ‘‘Prognosis of patients with chronic hepatitis B in France (2008–2013): A nationwide, observational and hospital-based study”. J Hepatol (2017), http://dx.doi.org/10.1016/j.jhep.2017.02.016